Expertise in
4
conditions

Stephen J. Falk

Bristol, ENG, GB 
Expertise in
4
conditions
Bristol, ENG, GB 

Overview

Stephen Falk practices practicing medicine in Bristol, United Kingdom.

Mr. Falk is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Esophageal Cancer, Colorectal Cancer, and PIK3CA-Related Overgrowth Spectrum.

He is actively involved in clinical research, co-authoring 56 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Bristol, ENG, United Kingdom
Other Locations
Sutton Upon Derwent, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Caprelsa (Vandetanib)
Study Phase: Phase 2
A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer
A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug, Radiation
Study Drugs: Nab-paclitaxel, Nelfinavir, Capecitabine, Gemcitabine
Study Phase: Phase 1/Phase 2
Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC or FLOT Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction
Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC or FLOT Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Radiation, Drug
Study Drugs: Epirubicin, Cisplatin / Oxaliplatin, 5 Flourouracil/ Capecitabine, Paclitaxel, Carboplatin, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil
Study Phase: Phase 3
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.
Enrollment Status: Completed
Publish Date: January 28, 2020
Intervention Type: Other, Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

56 Total Publications

Personalising radiotherapy dose in anal cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials.
Personalising radiotherapy dose in anal cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: March 13, 2026

Frequently Asked Questions about Stephen J. Falk

Is Stephen J. Falk a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Stephen J. Falk is classified as an Advanced expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stephen J. Falk participate in research or clinical trials?

Yes. Stephen J. Falk has published 56 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Stephen J. Falk's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Falk's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile